

SURG PATH REPORT

COLLECTION DATE/TIME:

1st Specimen collected on [REDACTED]

Accessioned on [REDACTED]

FINAL DIAGNOSIS ----- Pathologist: [REDACTED]

1. LYMPH NODE, R4 (RESECTION): ONE (1) LYMPH NODE AND ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. NEGATIVE FOR CARCINOMA.

2. LYMPH NODE, L4 (RESECTION): ONE (1) LYMPH NODE AND ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. NEGATIVE FOR CARCINOMA.

3. LUNG, RIGHT UPPER LOBE (LOBECTOMY):

SPECIMEN TYPE:

Lobectomy

TUMOR SITE:

Right upper lobe

HISTOLOGIC TYPE:

Adenocarcinoma, solid type with clear cell change

TUMOR SIZE:

Greatest dimension: 7.5 cm

HISTOLOGIC GRADE:

G3: Poorly differentiated

LYMPH NODES:

All 17 nodes negative for tumor (includes parts 1-7)

DIRECT EXTENSION OF TUMOR:

The tumor extends subpleurally but does not involve the pleural surface

EXTENT OF INVASION (7th Edition, AJCC):

PRIMARY TUMOR:

pT3: Tumor which is >7 cm or invades chest wall, diaphragm, mediastinal pleura, or parietal pericardium, or involves main bronchus <2 cm from carina or associated with total atelectasis or separate tumor nodule in the same lobe

REGIONAL LYMPH NODES:

pNO: No regional lymph node metastasis

DISTANT METASTASIS:

pMX: Cannot be assessed

MARGINS:

Margins uninvolved by invasive carcinoma

Distance of invasive carcinoma from nearest margin: 4.0 cm (bronchial margin)

VENOUS/ARTERIAL (LARGE VESSEL) INVASION:

Absent

LYMPHATIC (SMALL VESSEL) INVASION:

Absent

ADDITIONAL PATHOLOGIC FINDINGS:

Immunohistochemistry demonstrates that the tumor cells are TTF-1 (diffuse) and Napsin-A (variable) positive. An immunostain for p63 shows patchy, variable staining of the tumor cells. Thsi staining

\*\*\* Unofficial lab results - do not file in patient chart. \*\*\*

\*\*\* Contact medical records for official chart copy. \*\*\*

UNLESS OTHERWISE NOTED ON THE DETAIL PAGE, ALL LAB RESULTS PERFORMED AT:

LAB RESULTS

SP-CONS - SURG PATH REPORT - [REDACTED]

pattern supports the diagnosis.

Background lung shows emphysematous changes and organizing lung injury (fibroblast foci) adjacent to the tumor.

4. LYMPH NODE, STATION 1 (RESECTION): ONE (1) LYMPH NODE AND ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR.

5. LYMPH NODE, R4 (RESECTION): ONE (1) LYMPH NODE, NEGATIVE FOR TUMOR.

6. LYMPH NODE, 10R (RESECTION): THREE (3) LYMPH NODES, NEGATIVE FOR TUMOR.

7. LYMPH NODE, STATION 7 (RESECTION): ONE (1) LYMPH NODE AND ASSOCIATED FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR.

Note: EGFR and KRAS mutation analysis studies are pending and will be reported separately.

ADDENDUM ----- Pathologist: [REDACTED]  
KRAS MUTATION ANALYSIS IS NEGATIVE. NO MUTATIONS WERE IDENTIFIED AT CODONS 12 AND 13 OF THE KRAS GENE.

EGFR MUTATION ANALYSIS IS NEGATIVE. NO MUTATIONS WERE DETECTED AT EXONS 18-21 OF THE EGFR GENE [REDACTED] [REDACTED]

NOTE: A copy of the complete report is available in [REDACTED] and is on file in the molecular pathology laboratory.

See [REDACTED] Clinical Document dated [REDACTED] for official report.

Reported by:

The [REDACTED] Surgical Pathology

[REDACTED]  
Final Report Signed on [REDACTED]

Addendum added on [REDACTED]